Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012, Article ID 618574, 3 pages
http://dx.doi.org/10.1155/2012/618574
Research Article

Predictive Value of Positive Surgical Margins after Radical Prostatectomy for Lymph Node Metastasis in Locally Advanced Prostate Carcinoma

Department of Urology, St. Josef Medical Centre, University of Regensburg, Landshuter Straße 65, 93053 Regensburg, Germany

Received 1 July 2011; Accepted 4 August 2011

Academic Editor: Maximilian Burger

Copyright © 2012 Wolfgang Otto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Gontero, G. Marchioro, R. Pisani et al., “Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study,” European Urology, vol. 51, no. 4, pp. 922–930, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. R. Ghavamian, E. J. Bergstralh, M. L. Blute, J. Slezak, and H. Zincke, “Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison,” Journal of Urology, vol. 161, no. 4, pp. 1223–1228, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Engel, P. J. Bastian, H. Baur et al., “Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer,” European Urology, vol. 57, no. 5, pp. 754–761, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. L. F. Da Pozzo, C. Cozzarini, A. Briganti et al., “Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy,” European Urology, vol. 55, no. 5, pp. 1003–1011, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. Roach III, C. Marquez, H. S. Yuo et al., “Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason Score in men with clinically localized prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 28, no. 1, pp. 33–37, 1994. View at Google Scholar · View at Scopus
  6. S. Rahman, H. Cosmatos, G. Dave, S. Williams, and M. Tome, “Predicting pelvic lymph node involvement in current-era prostate cancer,” International Journal of Radiation Oncology. In press.
  7. M. Spahn, S. Joniau, P. Gontero et al., “Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients,” European Urology, vol. 58, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. P. Gontero, M. Spahn, B. Tombal et al., “Is there a prostate-specific antigen upper limit for radical prostatectomy?” British Journal of Urology International. In press.
  9. M. Spahn, C. Weiss, P. Bader et al., “Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation,” Urologia Internationalis, vol. 84, no. 2, pp. 164–173, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. S. Connolly, S. F. Oon, C. Carroll et al., “Radical prostatectomy outcome when performed with PSA above 20 ng/ml,” Irish Medical Journal, vol. 104, no. 4, pp. 108–111, 2011. View at Google Scholar
  11. J. J. Oh, S. K. Hong, S. S. Byun, G. Choe, and S. E. Lee, “Prognostic significance of positive surgical margins after radical prostatectomy among pT2 and pT3a prostate cancer,” Urologic Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed